Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals reports developments across its critical care and targeted oncology business, including activity at majority-owned subsidiary Citius Oncology. The company’s recurring updates center on LYMPHIR (denileukin diftitox-cxdl), an engineered IL-2 diphtheria toxin fusion protein approved for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.
Company news also covers LYMPHIR commercialization, U.S. launch progress, international access through Named Patient Programs, and investigator-initiated oncology studies involving gynecologic cancers and diffuse large B-cell lymphoma. Capital updates include registered direct offerings, warrant issuances, non-dilutive funding and other financing actions that support product commercialization and development programs.
Citius Oncology (Nasdaq: CTOR) announced its first shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe via a regional distribution partner on April 29, 2026, expanding patient access outside the United States.
LYMPHIR will be available through Named Patient Programs in specific countries under local regulations; it lacks EMA marketing authorization. The company continues U.S. commercial rollout after FDA approval in August 2024 and a December 2025 U.S. launch.
Citius Pharmaceuticals (Nasdaq: CTXR) closed a registered direct offering priced at-the-market, selling 5,076,143 shares (or pre-funded warrants) at $0.985 per share and issuing unregistered warrants to purchase up to 5,076,143 shares at a $0.86 exercise price.
The aggregate gross proceeds were approximately $5.0 million before placement agent fees and expenses. The company intends to use net proceeds to support the commercial launch of LYMPHIR™, product development and general corporate purposes. H.C. Wainwright acted as exclusive placement agent.
Citius Pharmaceuticals (Nasdaq: CTXR) announced a registered direct offering of 5,076,143 shares (or pre-funded warrants) at $0.985 per share and a concurrent private placement of unregistered warrants to purchase up to 5,076,143 shares at an $0.86 exercise price. Gross proceeds are expected to be approximately $5 million, with closing on or about April 24, 2026. The company intends to use net proceeds to support the commercial launch of LYMPHIR™, development programs, and general corporate purposes.
Citius Oncology (Nasdaq: CTOR) provided a commercial update on the U.S. launch of LYMPHIR for cutaneous T‑cell lymphoma on March 31, 2026. Early metrics show sequential order growth, 83% of target accounts progressing formulary review, ~135 health plans covering ~80% of lives, and no reported reimbursement denials. Clinical collaborations reported positive topline data at ASTCT 2026 and completed Phase I results at UPMC, with ongoing analyses and next‑stage discussions.
Commercial supply, international distribution agreements, and upcoming field team onboarding support continued launch expansion.
Citius Oncology (Nasdaq: CTOR) will attend the USCLC Annual Workshop on March 26, 2026 in Denver to discuss cutaneous T‑cell lymphoma (CTCL) care and clinical experience with LYMPHIR™ (denileukin diftitox‑cxdl), which the company recently launched in the U.S. The team will hold one‑on‑one meetings with CTCL specialists.
Citius Oncology (Nasdaq: CTOR) reported positive topline Phase 1 results for LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab in relapsed or refractory gynecologic cancers on March 10, 2026. In 25 evaluable patients, no unexpected safety signals or serious immune-related adverse events were observed.
The trial showed a 24% objective response rate (ORR) and a 48% clinical benefit rate (CBR) among 21 evaluable patients, and full results will be presented at an international cancer conference later this year.
Citius Oncology (Nasdaq: CTOR) reported preliminary Phase 1 topline data of LYMPHIR (E7777) given prior to commercial CD19 CAR‑T in 14 high‑risk relapsed/refractory DLBCL patients.
Key results: ORR 86% (CR 57%, PR 29%) at one month; one‑year PFS 77% (95% CI 43–92%) and OS 84% (95% CI 49–96%). LYMPHIR produced Treg depletion in nearly all patients and showed no dose‑limiting toxicities through 9 µg/kg; adverse events were manageable. Data were presented at the 2026 ASTCT/CIBMTR Tandem Meetings.
Citius Pharmaceuticals (Nasdaq: CTXR) received $3.8 million in non-dilutive capital through New Jersey's Technology Business Tax Certificate Transfer Program (NOL Program) funded by the New Jersey Economic Development Authority on Feb 24, 2026.
The funding strengthened the company's balance sheet and financial flexibility and is intended to support the commercial launch of LYMPHIR and advancement of its late-stage pipeline programs, per management.
Citius Oncology (Nasdaq: CTOR) reported first reported revenue of $3.9 million from the December 2025 commercial launch of LYMPHIR (denileukin diftitox-cxdl) and provided fiscal Q1 2026 results for the quarter ended December 31, 2025. The company is now a commercial-stage oncology firm with an FDA-approved IL-2 receptor-directed therapy for relapsed or refractory Stage I–III CTCL.
Other Q1 highlights include $7.3 million cash on hand, a December registered offering that raised net proceeds of $15.1 million, R&D of $1.0 million, G&A of $2.9 million, and a net loss of $5.5 million ($(0.06) per share).
Citius Pharmaceuticals (Nasdaq: CTXR) reported first-quarter fiscal 2026 results and the first reported revenue after the December 2025 commercial launch of LYMPHIR. Consolidated revenue was $3.9 million from initial U.S. distributor sales. Cash totaled $7.7 million and the company generated approximately $20.9 million net proceeds from equity financings. R&D expense declined to $1.6 million, general and administrative expense was $5.7 million, stock-based compensation rose to $4.3 million, and net loss narrowed to $8.2 million (−16% year-over-year). The company reported early physician adoption, international named-patient agreements, and ongoing investigator-initiated studies exploring LYMPHIR combinations.